The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Open accessAbstract
BACKGROUND: Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. METHODS: A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 microg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks. RESULTS: A significantly higher proportion of patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 percent, P<0.001) or peginterferon alfa-2a alone (56 percent vs. 29 percent, P<0.001). The proportions of patients with HCV genotype 1 who had sustained virologic responses were 46 percent, 36 percent, and 21 percent, respectively, for the three regimens. Among patients with HCV genotype 1 and high base-line levels of HCV RNA, the proportions of those with sustained virologic responses were 41 percent, 33 percent, and 13 percent, respectively. The overall safety profiles of the three treatment regimens were similar; the incidence of influenza-like symptoms and depression was lower in the groups receiving peginterferon alfa-2a than in the group receiving interferon alfa-2b plus ribavirin. CONCLUSIONS: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Self-citationMcHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Self-citationPoynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Self-citationPeginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432302 · Cited by 874
Self-citationEASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999
(1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80154-8 · Cited by 700
Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C., Schiff, E. R., Goodman, Z. D., Laughlin, M., Yao, R., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.26371 · Cited by 668
Self-citation
Cited by
Items 101–176 of 176
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi-Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 338
Cardoso, A.-C., Moucari, R., Figueiredo-Mendes, C., Ripault, M.-P., Giuily, N., Castelnau, C., Boyer, N., Asselah, T., Martinot-Peignoux, M., Maylin, S., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.028 · Cited by 333
Swain, M. G., Lai, M., Shiffman, M. L., Cooksley, W. G. E., Zeuzem, S., Dieterich, D. T., Abergel, A., Pessôa, M. G., Lin, A., Tietz, A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.009 · Cited by 328
Self-citationFrom non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328
McCarthy, J. J., Li, J. H., Thompson, A., Suchindran, S., Lao, X. Q., Patel, K., Tillmann, H. L., Muir, A. J., & McHutchison, J. G. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.009 · Cited by 327
Limited Uptake of Hepatitis C Treatment Among Injection Drug Users
Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., Strathdee, S. A., & Thomas, D. L. (2008) · Journal of Community Health · doi:10.1007/s10900-007-9083-3 · Cited by 327
Treatment predictors of a sustained virologic response in hepatitis B and C
Kau, A., Vermehren, J., & Sarrazin, C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.013 · Cited by 324
Development of Pharmaceutical Nanomedicines: From the Bench to the Market
Halwani, A. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010106 · Cited by 324
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C
Maylin, S., Martinot–Peignoux, M., Moucari, R., Boyer, N., Ripault, M., Cazals–Hatem, D., Giuily, N., Castelnau, C., Cardoso, A. C., Asselah, T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.044 · Cited by 321
Use and interpretation of virological tests for hepatitis C
Pawlotsky, J.-M. (2002) · Hepatology · doi:10.1053/jhep.2002.36815 · Cited by 320
Salmon-Ceron, D., Lewden, C., Morlat, P., Bévilacqua, S., Jougla, E., Bonnet, F., Héripret, L., Costagliola, D., May, T., & Chêne, G. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.01.022 · Cited by 319
Viral hepatitis and HIV coinfection
Sulkowski, M. S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.009 · Cited by 316
Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral
Samuel, C. E. (2011) · Virology · doi:10.1016/j.virol.2010.12.004 · Cited by 315
Sarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S. K., Hussain, M., Shah, A., Cutler, D., Zhang, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.041 · Cited by 310
Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., Goldberg, D. J., & Hellard, M. E. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit306 · Cited by 309
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
RNA Viruses: ROS-Mediated Cell Death
Reshi, M. L., Su, Y.-C., & Hong, J.-R. (2014) · International Journal of Cell Biology · doi:10.1155/2014/467452 · Cited by 305
McMahan, R. H., Golden-Mason, L., Nishimura, M. I., McMahon, B. J., Kemper, M., Allen, T. M., Gretch, D. R., & Rosen, H. R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43127 · Cited by 305
Increasing burden of liver disease in patients with HIV infection
Joshi, D., O'Grady, J., Dieterich, D., Gazzard, B., & Agarwal, K. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62001-6 · Cited by 305
Sarasin-Filipowicz, M., Krol, J., Markiewicz, I., Heim, M. H., & Filipowicz, W. (2009) · Nature Medicine · doi:10.1038/nm.1902 · Cited by 304
Jacobson, I. M., Brown, R. S., Freilich, B., Afdhal, N., Kwo, P. Y., Santoro, J., Becker, S., Wakil, A. E., Pound, D., Godofsky, E., et al. (2007) · Hepatology · doi:10.1002/hep.21932 · Cited by 304
Sulkowski, M. S., Eron, J. J., Wyles, D., Trinh, R., Lalezari, J., Wang, C., Slim, J., Bhatti, L., Gathe, J., Ruane, P. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.1328 · Cited by 303
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy: Prevalence and Prediction
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 299
Castéra, L., Hézode, C., Roudot-Thoraval, F., Bastie, A., Zafrani, E.-S., Pawlotsky, J.-M., & Dhumeaux, D. (2003) · Gut · doi:10.1136/gut.52.2.288 · Cited by 298
Self-citationInterferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
Optimal therapy of hepatitis C
Di Bisceglie, A. M., & Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360716 · Cited by 297
Steatosis affects chronic hepatitis C progression in a genotype specific way
Rubbia-Brandt, L., Fabris, P., Paganin, S., Leandro, G., Male, P.-J., Giostra, E., Carlotto, A., Bozzola, L., Smedile, A., & Negro, F. (2004) · Gut · doi:10.1136/gut.2003.018770 · Cited by 297
Antiviral strategies in hepatitis C virus infection
Sarrazin, C., Hézode, C., Zeuzem, S., & Pawlotsky, J.-M. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60010-5 · Cited by 283
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Banerjee, S. S., Aher, N., Patil, R., & Khandare, J. (2012) · Journal of Drug Delivery · doi:10.1155/2012/103973 · Cited by 282
Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., Arakawa, Y., Hashimoto, E., Hirota, K., Yoshida, H., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-2-200501180-00009 · Cited by 282
Global control of hepatitis C: where challenge meets opportunity
Thomas, D. L. (2013) · Nature Medicine · doi:10.1038/nm.3184 · Cited by 280
Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280
Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., & Maeda, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00002 · Cited by 278
The way forward in HCV treatment — finding the right path
Manns, M. P., Foster, G. R., Rockstroh, J. K., Zeuzem, S., Zoulim, F., & Houghton, M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2411 · Cited by 278
Sofia, M. J., Chang, W., Furman, P. A., Mosley, R. T., & Ross, B. S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201384j · Cited by 275
Kwong, A. D., Kauffman, R. S., Hurter, P., & Mueller, P. (2011) · Nature Biotechnology · doi:10.1038/nbt.2020 · Cited by 274
Martin‐Carbonero, L., Benhamou, Y., Puoti, M., Berenguer, J., Mallolas, J., Quereda, C., Arizcorreta, A., Gonzalez, A., Rockstroh, J., Asensi, V., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380130 · Cited by 272
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Pearlman, B. L., Ehleben, C., & Saifee, S. (2007) · Hepatology · doi:10.1002/hep.21919 · Cited by 269
Njoroge, F. G., Chen, K. X., Shih, N.-Y., & Piwinski, J. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700109k · Cited by 266
Feld, J. J., Nanda, S., Huang, Y., Chen, W., Cam, M., Pusek, S. N., Schweigler, L. M., Theodore, D., Zacks, S. L., Liang, J. T., et al. (2007) · Hepatology · doi:10.1002/hep.21853 · Cited by 265
Self-citationPearlman, B. L., & Traub, N. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir076 · Cited by 261
Zeuzem, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00033 · Cited by 261
Side effects of therapy for chronic hepatitis C
Russo, M. W., & Fried, M. W. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00394-9 · Cited by 261
Self-citationAkuta, N., Suzuki, F., Hirakawa, M., Kawamura, Y., Yatsuji, H., Sezaki, H., Suzuki, Y., Hosaka, T., Kobayashi, M., Kobayashi, M., et al. (2010) · Hepatology · doi:10.1002/hep.23690 · Cited by 256
Apolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus Particles
Jiang, J., & Luo, G. (2009) · Journal of Virology · doi:10.1128/jvi.01476-09 · Cited by 255
van de Laar, T. J., Matthews, G. V., Prins, M., & Danta, M. (2010) · AIDS · doi:10.1097/qad.0b013e32833c11a5 · Cited by 252
Bataller, R., Paik, Y.-H., Lindquist, J. N., Lemasters, J. J., & Brenner, D. A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.018 · Cited by 252
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
Su, K.-P., Lai, H.-C., Yang, H.-T., Su, W.-P., Peng, C.-Y., Chang, J. P.-C., Chang, H.-C., & Pariante, C. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.01.008 · Cited by 205
When should decision-analytic modeling be used in the economic evaluation of health care?
Siebert, U. (2003) · The European Journal of Health Economics · doi:10.1007/s10198-003-0205-2 · Cited by 181
Abnormalities of lipid metabolism in hepatitis C virus infection
Negro, F. (2010) · Gut · doi:10.1136/gut.2009.192732 · Cited by 162
Drugs affecting thyroid function
Barbesino, G. (2010) · Thyroid · doi:10.1089/thy.2010.1635 · Cited by 146
RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03316.x · Cited by 142
Indications, patient selection and timing of referral for lung transplantation
Glanville, A. R., & Estenne, M. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00039003 · Cited by 101
Rigopoulou, E. I., Abbott, W. G. H., Haigh, P., & Naoumov, N. V. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.06.003 · Cited by 98
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100
Psychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86
Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States
Scott, J. D., Unruh, K. T., Catlin, M. C., Merrill, J. O., Tauben, D. J., Rosenblatt, R., Buchwald, D., Doorenbos, A., Towle, C., Ramers, C. B., et al. (2012) · Journal of Telemedicine and Telecare · doi:10.1258/jtt.2012.gth113 · Cited by 85
Antifibrotic Agents for Liver Disease
Albanis, E., & Friedman, S. L. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01143.x · Cited by 68
Lamiridosins, Hepatitis C Virus Entry Inhibitors from Lamium album
Zhang, H., Rothwangl, K., Mesecar, A. D., Sabahi, A., Rong, L., & Fong, H. H. S. (2009) · Journal of Natural Products · doi:10.1021/np900549e · Cited by 65
Franzen, P. L., Buysse, D. J., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.02.011 · Cited by 62
Hoyo-Becerra, C., Huebener, A., Trippler, M., Lutterbeck, M., Liu, Z. J., Truebner, K., Bajanowski, T., Gerken, G., Hermann, D. M., & Schlaak, J. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083149 · Cited by 49
Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., Mauceri, B., Abate, G., Boemi, P., Di Pino, A., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d88af5 · Cited by 37
Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells
Hou, W.-H., Rossi, L., Shan, Y., Zheng, J.-Y., Lambrecht, R. W., & Bonkovsky, H. L. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4499 · Cited by 35
for the FarmaPEG Study Group, García-García, I., González-Delgado, C. A., Valenzuela-Silva, C. M., Díaz-Machado, A., Cruz-Díaz, M., Nodarse-Cuní, H., Pérez-Pérez, O., Bermúdez-Badell, C. H., Ferrero-Bibilonia, J., et al. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-15 · Cited by 33
Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?
Evon, D. M., Golin, C. E., Fried, M. W., & Keefe, F. J. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0029030 · Cited by 32
Self-citationFumaz, C. R., Muñoz-Moreno, J. A., Ballesteros, A. L., Paredes, R., Ferrer, M. J., Salas, A., Fuster, D., Masmitjà, E., Pérez-Álvarez, N., Gómez, G., et al. (2007) · AIDS Care · doi:10.1080/09540120600645539 · Cited by 30
Schlaak, J. F., Trippler, M., Hoyo-Becerra, C., Erim, Y., Kis, B., Wang, B., Scherbaum, N., & Gerken, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038668 · Cited by 25
The hepatitis C self‐management programme: a randomized controlled trial
Groessl, E. J., Weingart, K. R., Stepnowsky, C. J., Gifford, A. L., Asch, S. M., & Ho, S. B. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01328.x · Cited by 25
Honda, M., Nakamura, M., Tateno, M., Sakai, A., Shimakami, T., Shirasaki, T., Yamashita, T., Arai, K., Yamashita, T., Sakai, Y., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.036 · Cited by 21
Development of the Hepatitis C Self-Management Program
Groessl, E. J., Weingart, K. R., Gifford, A. L., Asch, S. M., & Ho, S. B. (2011) · Patient Education and Counseling · doi:10.1016/j.pec.2010.06.006 · Cited by 14
Reliability and validity of a self‐efficacy instrument for hepatitis C antiviral treatment regimens
Bonner, J. E., Esserman, D., & Evon, D. M. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01550.x · Cited by 8
Evon, D. M., Golin, C. E., Ruffin, R., & Fried, M. W. (2017) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2017.03.008 · Cited by 5
Self-citation
Metadata
- Authors
- Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., & Yu, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-09-26
- Volume
- 347
- Issue
- 13
- Pages
- 975-982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2027545702
- Cited by
- 6,389
- References
- 19
- FWCI
- 201.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.